Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Operations (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Cash from Operations for 3 consecutive years, with 30122000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 31.1% to 30122000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 129794000.0 through Dec 2025, up 33.24% year-over-year, with the annual reading at 129794000.0 for FY2025, 33.24% up from the prior year.
  • Cash from Operations for Q4 2025 was 30122000.0 at Inhibrx Biosciences, up from 33824000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 29953000.0 in Q2 2025, with the low at 63050000.0 in Q1 2024.
  • Average Cash from Operations over 3 years is 43526900.0, with a median of 39807500.0 recorded in 2024.
  • Peak annual rise in Cash from Operations hit 47.78% in 2025, while the deepest fall reached 11.7% in 2025.
  • Over 3 years, Cash from Operations stood at 56821000.0 in 2023, then grew by 23.06% to 43720000.0 in 2024, then skyrocketed by 31.1% to 30122000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 30122000.0, 33824000.0, and 29953000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.